Corium International, Inc. (NASDAQ:CORI) major shareholder Healthcare Master Fun Broadfin sold 218,100 shares of the stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $11.01, for a total transaction of $2,401,281.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Corium International, Inc. (CORI) opened at 10.26 on Tuesday. Corium International, Inc. has a one year low of $2.67 and a one year high of $11.37. The firm’s market cap is $366.71 million. The company has a 50 day moving average of $10.04 and a 200-day moving average of $7.59.
Corium International (NASDAQ:CORI) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.13). The company had revenue of $8.11 million for the quarter, compared to analyst estimates of $8.71 million. Corium International had a negative return on equity of 673.17% and a negative net margin of 145.60%. On average, analysts expect that Corium International, Inc. will post ($1.70) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in CORI. Bank of New York Mellon Corp increased its position in Corium International by 118.1% during the 1st quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 13,683 shares in the last quarter. New York State Common Retirement Fund acquired a new position in Corium International during the 2nd quarter worth approximately $158,000. California State Teachers Retirement System acquired a new position in Corium International during the 2nd quarter worth approximately $263,000. Teachers Advisors LLC acquired a new position in Corium International during the 2nd quarter worth approximately $272,000. Finally, TIAA CREF Investment Management LLC acquired a new position in Corium International in the 2nd quarter valued at approximately $411,000. Institutional investors and hedge funds own 90.14% of the company’s stock.
Several research analysts recently issued reports on CORI shares. WBB Securities raised shares of Corium International to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, July 7th. Jefferies Group LLC reissued a “buy” rating and issued a $8.00 price target on shares of Corium International in a research report on Wednesday, July 19th. BidaskClub raised shares of Corium International from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine lowered shares of Corium International from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Finally, Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $13.00.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with our FREE daily email newsletter.